SELB Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Cartesian Therapeutics, Inc. - Mentions: RNAC

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

2 years ago - By: Cartesian Therapeutics, Inc. - Mentions: RNAC

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

2 years ago - By: Brodsky & Smith LLC - Mentions: WAVD GRPH CSTR ONB

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

2 years ago - By: Benzinga

Analyst Ratings for Selecta Biosciences

3 years ago - By: Benzinga

Recap: Selecta Biosciences Q1 Earnings

2 years ago - By: Selecta Biosciences, Inc. - Mentions: RNAC

Selecta Biosciences Announces Merger with Cartesian Therapeutics

2 years ago - By: Selecta Biosciences, Inc.

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

2 years ago - By: Seeking Alpha

Selecta Biosciences files for $200M mixed shelf (NASDAQ:SELB)

3 years ago - By: Swedish Orphan Biovitrum AB

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

2 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

2 years ago - By: Seeking Alpha - Mentions: ABOS ESTA RCUS BBIO ...

Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023 (BBIO)

2 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology

3 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

3 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

3 years ago - By: InvestorPlace - Mentions: CISO PEAR CVKD FRC ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

3 years ago - By: Seeking Alpha

Selecta stock surges ~20% as gout drug SEL-212 meets main goal in 2 trials

3 years ago - By: Selecta Biosciences, Inc.; Sobi

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint

3 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

3 years ago - By: InvestorPlace - Mentions: REGN VRTX HRMY GNFT ...

The 7 Best Biotech Stocks to Buy for February 2023

3 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference

3 years ago - By: Seeking Alpha

Selecta Biosciences stock rises 10% on license deal with Astellas for Xork

3 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences Provides Business Update and Outlook for 2023

3 years ago - By: Astellas Pharma Inc.

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

3 years ago - By: Selecta Biosciences, Inc.

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program

3 years ago - By: Seeking Alpha

SELECTA BIOSCIENCES INC (SELB) Stock News

SELB Latest News, Press Relases and Analysis

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

Analyst Ratings for Selecta Biosciences

Recap: Selecta Biosciences Q1 Earnings

Selecta Biosciences Announces Merger with Cartesian Therapeutics

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

Selecta Biosciences files for $200M mixed shelf (NASDAQ:SELB)

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023 (BBIO)

Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology

Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Selecta stock surges ~20% as gout drug SEL-212 meets main goal in 2 trials

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

The 7 Best Biotech Stocks to Buy for February 2023

Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference

Selecta Biosciences stock rises 10% on license deal with Astellas for Xork

Selecta Biosciences Provides Business Update and Outlook for 2023

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program

Selecta Biosciences appoints Protara Therapeutics's Blaine Davis as new CFO (NASDAQ:SELB)